메뉴 건너뛰기




Volumn 377, Issue 13, 2017, Pages 1217-1227

Effects of anacetrapib in patients with atherosclerotic vascular disease

(2,335)  Bowman, Louise a   Hopewell, Jemma C a   Chen, Fang a   Wallendszus, Karl a   Stevens, William a   Collins, Rory a   Wiviott, Stephen D b   Cannon, Christopher P b   Braunwald, Eugene b   Sammons, Emily a   Landray, Martin J a   Jiang, L c   Armitage, J c   Haynes, R c   Maggioni, A P c   Angermann, C E c   Ertl, G c   Wanner, C c   Pedersen, T c   Goto, S c   more..

c NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANACETRAPIB; ATORVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; CETP PROTEIN, HUMAN; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; OXAZOLIDINONE DERIVATIVE;

EID: 85030329600     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1706444     Document Type: Article
Times cited : (794)

References (30)
  • 1
    • 26244432388 scopus 로고    scopus 로고
    • Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins
    • Baigent C, Keech A, Kearney PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet 2005; 366:1267-78.
    • (2005) Lancet , vol.366 , pp. 1267-1278
    • Baigent, C.1    Keech, A.2    Kearney, P.M.3
  • 2
    • 78449281377 scopus 로고    scopus 로고
    • Efficacy and safety of more intensive lowering of LDL cholesterol: A meta-analysis of data from 170,000 participants in 26 randomised trials
    • Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376:1670-81.
    • (2010) Lancet , vol.376 , pp. 1670-1681
    • Baigent, C.1    Blackwell, L.2    Emberson, J.3
  • 3
    • 84931411520 scopus 로고    scopus 로고
    • Ezetimibe added to statin therapy after acute coronary syndromes
    • Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372:2387-97.
    • (2015) N Engl J Med , vol.372 , pp. 2387-2397
    • Cannon, C.P.1    Blazing, M.A.2    Giugliano, R.P.3
  • 4
    • 85017341929 scopus 로고    scopus 로고
    • Evolocumab and clinical outcomes in patients with cardiovascular disease
    • Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376:1713-22.
    • (2017) N Engl J Med , vol.376 , pp. 1713-1722
    • Sabatine, M.S.1    Giugliano, R.P.2    Keech, A.C.3
  • 5
    • 84904252744 scopus 로고    scopus 로고
    • Effects of extended-release niacin with laropiprant in high-risk patients
    • The HPS2-THRIVE Collaborative Group. Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med 2014;371:203-12.
    • (2014) N Engl J Med , vol.371 , pp. 203-212
  • 6
    • 84855171302 scopus 로고    scopus 로고
    • Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy
    • The AIM-HIGH Investigators. Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy. N Engl J Med 2011;365:2255-67.
    • (2011) N Engl J Med , vol.365 , pp. 2255-2267
  • 7
    • 0027275449 scopus 로고
    • Plasma cholesteryl ester transfer protein
    • Tall AR. Plasma cholesteryl ester transfer protein. J Lipid Res 1993;34:1255-74.
    • (1993) J Lipid Res , vol.34 , pp. 1255-1274
    • Tall, A.R.1
  • 8
    • 36348975228 scopus 로고    scopus 로고
    • Effects of torcetrapib in patients at high risk for coronary events
    • Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007;357:2109-22.
    • (2007) N Engl J Med , vol.357 , pp. 2109-2122
    • Barter, P.J.1    Caulfield, M.2    Eriksson, M.3
  • 9
    • 84870045994 scopus 로고    scopus 로고
    • Effects of dalcetrapib in patients with a recent acute coronary syndrome
    • Schwartz GG, Olsson AG, Abt M, et al. Effects of dalcetrapib in patients with a recent acute coronary syndrome. N Engl J Med 2012;367:2089-99.
    • (2012) N Engl J Med , vol.367 , pp. 2089-2099
    • Schwartz, G.G.1    Olsson, A.G.2    Abt, M.3
  • 10
    • 85019790381 scopus 로고    scopus 로고
    • Evacetrapib and cardiovascular outcomes in high-risk vascular disease
    • Lincoff AM, Nicholls SJ, Riesmeyer JS, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular disease. N Engl J Med 2017;376:1933-42.
    • (2017) N Engl J Med , vol.376 , pp. 1933-1942
    • Lincoff, A.M.1    Nicholls, S.J.2    Riesmeyer, J.S.3
  • 11
    • 78549235583 scopus 로고    scopus 로고
    • Safety of anacetrapib in patients with or at high risk for coronary heart disease
    • Cannon CP, Shah S, Dansky HM, et al. Safety of anacetrapib in patients with or at high risk for coronary heart disease. N Engl J Med 2010;363:2406-15.
    • (2010) N Engl J Med , vol.363 , pp. 2406-2415
    • Cannon, C.P.1    Shah, S.2    Dansky, H.M.3
  • 12
    • 84930088585 scopus 로고    scopus 로고
    • Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): A randomised, double-blind, placebo-controlled, phase 3 study
    • Kastelein JJ, Besseling J, Shah S, et al. Anacetrapib as lipid-modifying therapy in patients with heterozygous familial hypercholesterolaemia (REALIZE): a randomised, double-blind, placebo-controlled, phase 3 study. Lancet 2015;385:2153-61.
    • (2015) Lancet , vol.385 , pp. 2153-2161
    • Kastelein, J.J.1    Besseling, J.2    Shah, S.3
  • 13
    • 85015987700 scopus 로고    scopus 로고
    • Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL) — A large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: Trial design, recruitment, and baseline characteristics
    • REVEAL Collaborative Group. Randomized Evaluation of the Effects of Anacetrapib through Lipid-modification (REVEAL) — a large-scale, randomized, placebo-controlled trial of the clinical effects of anacetrapib among people with established vascular disease: trial design, recruitment, and baseline characteristics. Am Heart J 2017;187:182-90.
    • (2017) Am Heart J , vol.187 , pp. 182-190
  • 14
    • 0016799829 scopus 로고
    • Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial
    • Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-15.
    • (1975) Biometrics , vol.31 , pp. 103-115
    • Pocock, S.J.1    Simon, R.2
  • 15
    • 0021909115 scopus 로고
    • Beta blockade during and after myocardial infarction: An overview of the randomized trials
    • Yusuf S, Peto R, Lewis J, Collins R, Sleight P. Beta blockade during and after myocardial infarction: an overview of the randomized trials. Prog Cardiovasc Dis 1985;27:335-71.
    • (1985) Prog Cardiovasc Dis , vol.27 , pp. 335-371
    • Yusuf, S.1    Peto, R.2    Lewis, J.3    Collins, R.4    Sleight, P.5
  • 16
    • 84872459510 scopus 로고    scopus 로고
    • Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib
    • Davidson M, Liu SX, Barter P, et al. Measurement of LDL-C after treatment with the CETP inhibitor anacetrapib. J Lipid Res 2013;54:467-72.
    • (2013) J Lipid Res , vol.54 , pp. 467-472
    • Davidson, M.1    Liu, S.X.2    Barter, P.3
  • 17
    • 84945957097 scopus 로고    scopus 로고
    • CETP/LPL/LIPC gene polymorphisms and susceptibility to age-related macular degeneration
    • Wang YF, Han Y, Zhang R, Qin L, Wang MX, Ma L. CETP/LPL/LIPC gene polymorphisms and susceptibility to age-related macular degeneration. Sci Rep 2015;5:15711.
    • (2015) Sci Rep , vol.5 , pp. 15711
    • Wang, Y.F.1    Han, Y.2    Zhang, R.3    Qin, L.4    Wang, M.X.5    Ma, L.6
  • 18
    • 67650475219 scopus 로고    scopus 로고
    • Screening for mood and anxiety disorders with the five-item, the three-item, and the two-item Mental Health Inventory
    • Cuijpers P, Smits N, Donker T, ten Have M, de Graaf R. Screening for mood and anxiety disorders with the five-item, the three-item, and the two-item Mental Health Inventory. Psychiatry Res 2009; 168:250-5.
    • (2009) Psychiatry Res , vol.168 , pp. 250-255
    • Cuijpers, P.1    Smits, N.2    Donker, T.3    Ten Have, M.4    De Graaf, R.5
  • 19
    • 0037395785 scopus 로고    scopus 로고
    • Utility of TICS-M for the assessment of cognitive function in older adults
    • de Jager CA, Budge MM, Clarke R. Utility of TICS-M for the assessment of cognitive function in older adults. Int J Geriatr Psychiatry 2003;18:318-24.
    • (2003) Int J Geriatr Psychiatry , vol.18 , pp. 318-324
    • De Jager, C.A.1    Budge, M.M.2    Clarke, R.3
  • 20
    • 71749117559 scopus 로고    scopus 로고
    • Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial
    • Barter P. Lessons learned from the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Am J Cardiol 2009;104:Suppl:10E-15E.
    • (2009) Am J Cardiol , vol.104 , pp. 10E-15E
    • Barter, P.1
  • 21
    • 48149106322 scopus 로고    scopus 로고
    • Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone
    • Forrest MJ, Bloomfield D, Briscoe RJ, et al. Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone. Br J Pharmacol 2008;154:1465-73.
    • (2008) Br J Pharmacol , vol.154 , pp. 1465-1473
    • Forrest, M.J.1    Bloomfield, D.2    Briscoe, R.J.3
  • 22
    • 70450081001 scopus 로고    scopus 로고
    • Major lipids, apolipoproteins, and risk of vascular disease
    • Di Angelantonio E, Sarwar N, Perry P, et al. Major lipids, apolipoproteins, and risk of vascular disease. JAMA 2009;302: 1993-2000.
    • (2009) JAMA , vol.302 , pp. 1993-2000
    • Di Angelantonio, E.1    Sarwar, N.2    Perry, P.3
  • 23
    • 85020786942 scopus 로고    scopus 로고
    • Protein-truncating variants at the cholesteryl ester transfer protein gene and risk for coronary heart disease
    • Nomura A, Won HH, Khera AV, et al. Protein-truncating variants at the cholesteryl ester transfer protein gene and risk for coronary heart disease. Circ Res 2017; 121:81-8.
    • (2017) Circ Res , vol.121 , pp. 81-88
    • Nomura, A.1    Won, H.H.2    Khera, A.V.3
  • 24
    • 84989187956 scopus 로고    scopus 로고
    • Interpretation of the evidence for the efficacy and safety of statin therapy
    • Collins R, Reith C, Emberson J, et al. Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet 2016;388:2532-61.
    • (2016) Lancet , vol.388 , pp. 2532-2561
    • Collins, R.1    Reith, C.2    Emberson, J.3
  • 25
    • 58649091088 scopus 로고    scopus 로고
    • Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients
    • Bloomfield D, Carlson GL, Sapre A, et al. Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib as monotherapy and coadministered with atorvastatin in dyslipidemic patients. Am Heart J 2009;157(2):352-360.e2.
    • (2009) Am Heart J , vol.157 , Issue.2 , pp. 352-360.e2
    • Bloomfield, D.1    Carlson, G.L.2    Sapre, A.3
  • 26
    • 84984973611 scopus 로고    scopus 로고
    • Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial
    • Barter PJ, Rye KA, Tardif JC, et al. Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation 2011;124:555-62.
    • (2011) Circulation , vol.124 , pp. 555-562
    • Barter, P.J.1    Rye, K.A.2    Tardif, J.C.3
  • 28
    • 77549087054 scopus 로고    scopus 로고
    • Statins and risk of incident diabetes: A collaborative meta-analysis of randomised statin trials
    • Sattar N, Preiss D, Murray HM, et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010;375: 735-42.
    • (2010) Lancet , vol.375 , pp. 735-742
    • Sattar, N.1    Preiss, D.2    Murray, H.M.3
  • 29
    • 85018311954 scopus 로고    scopus 로고
    • Chronic administration of anacetrapib is associated with accumulation in adipose and slow elimination
    • April 5 (Epub ahead of print)
    • Krishna R, Gheyas F, Liu Y, et al. Chronic administration of anacetrapib is associated with accumulation in adipose and slow elimination. Clin Pharmacol Ther 2017 April 5 (Epub ahead of print).
    • (2017) Clin Pharmacol Ther
    • Krishna, R.1    Gheyas, F.2    Liu, Y.3
  • 30
    • 84908895008 scopus 로고    scopus 로고
    • Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study
    • Gotto AM Jr, Kher U, Chatterjee MS, et al. Lipids, safety parameters, and drug concentrations after an additional 2 years of treatment with anacetrapib in the DEFINE study. J Cardiovasc Pharmacol Ther 2014;19:543-9.
    • (2014) J Cardiovasc Pharmacol Ther , vol.19 , pp. 543-549
    • Gotto, A.M.1    Kher, U.2    Chatterjee, M.S.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.